Pramipexole in depression - a follow-up study

Phase 1

Recruiting

• Conditions: Depression; MedDRA version: 20.0Level: LLTClassification code: 10013981Term: Dysthymia Class: 10037175; MedDRA version: 21.1Level: LLTClassification code: 10004936Term: Bipolar depression Class: 10037175; MedDRA version: 21.1Level: PTClassification code: 10057840Term: Major depression Class: 100000004873; Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]

• Registration Number: CTIS2022-502270-17-00
• Lead Sponsor: Region Skane

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-11-15
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Previous participation in RCT testing the short-term efficacy of pramipexole vs placebo (EudraCT# 2022-001563-26)., Study participants randomized to pramipexole in the RCT who wish to continue with their treatment can enrol in the study., Study participants randomized to placebo in the RCT who fulfil the inclusion criteria after the RCT can enrol in the study., The research subject has given informed consent to participate in the study., Additional inclusion criterion for patients receiving placebo during the RCT:Anhedonia symptoms: 3 or 4 points on = 3 items of the Snaith-Hamilton Pleasure Scale (SHAPS-C). This has been adopted in previous studies as a definition of clinically significant anhedonia27.

Exclusion Criteria

Pregnancy, breastfeeding or planned pregnancy (if female)., Recently started psychotherapy (within 6 weeks)., Ongoing or planned ECT, ketamine or rTMS treatment, excluding maintenance ECT, ketamine or rTMS. (Maintenance treatment is defined as the use of ECT/ketamine/rTMS for a period exceeding 3 months after a series of ECT/ketamine/rTMS treatment in order to prevent the onset of a new episode)., Other medical conditions or other concomitant drug treatment (see section 13.5) which, in the opinion of the investigators, may affect the evaluability of the trial or conditions that increase trial risk. For example, Parkinson's disease, hepatic insufficiency, ongoing cancer not in remission for more than one year, older bariatric surgery with a known impact on absorption of extended-release tablets., Known or suspected allergy to any active substance or excipient in the medicinal product included in the trial., Participation in other treatment studies., Other reason, as assessed by the investigator, that prevents the research subject's participation, such as the risk that the research subject is unable to complete the trial (non-compliance)., High suicide risk according to the overall clinical assessment of the research physician., Ongoing substance abuse (within 6 months)., Diagnosis of current psychosis., Known diagnosis of Emotionally Unstable Personality Disorder., Treatment under LPT., History of or a strong clinical suspicion of impulse control disorder (including current binge-eating disorder) or a current ADHD diagnosis with hyperactivity., Diagnosis of intellectual disability, dementia, or other circumstance that makes it difficult to understand the meaning of participating in the trial and give informed consent., Diagnosis of renal failure (eGFR < 50 ml/min/1.73m2) or severe cardiovascular disease (specifically symptomatic heart failure NYHA Class II or higher). Blood samples from RCT are sufficient to rule this out.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified